"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...

Bluejay’s lead product candidate brelovitug (BJT-778) recently received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD).

Impress your Valentine at 980 Prime Steakhouse at the Chamonix Casino Hotel in Cripple Creek. Enjoy great food, wine pairings, and a romantic setting.

Cadrenal Therapeutics, a biopharmaceutical company listed on the Nasdaq under the ticker symbol CVKD, made a public announcement of leadership changes through an 8-K SEC filing on February 4, 2025.